argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Argenx SE announced new data for VYVGART in treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy at the 2026 American Academy of Neurology Annual Meeting. The data supports broader use of VYVGART across different patient populations.
Argenx SE presented new data for VYVGART at the 2026 American Academy of Neurology Annual Meeting in Chicago. The data includes results from the Phase 3 ADAPT OCULUS study, showing VYVGART's efficacy in treating ocular myasthenia gravis. VYVGART demonstrated significant improvement in disease symptoms in this patient population. The company plans to submit a supplemental Biologics License Application to the FDA to expand the label into ocular myasthenia gravis. Additional data from ADAPT SERON and ADHERE studies support VYVGART's efficacy and safety across different patient populations. Argenx is advancing its neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.